U.S. Markets close in 5 hrs 56 mins
  • S&P 500

    3,675.29
    +6.28 (+0.17%)
     
  • Dow 30

    29,995.97
    +112.18 (+0.38%)
     
  • Nasdaq

    12,415.68
    +66.32 (+0.54%)
     
  • Russell 2000

    1,845.13
    +7.11 (+0.39%)
     
  • Crude Oil

    45.23
    -0.05 (-0.11%)
     
  • Gold

    1,836.40
    +6.20 (+0.34%)
     
  • Silver

    23.97
    -0.11 (-0.46%)
     
  • EUR/USD

    1.2165
    +0.0050 (+0.4136%)
     
  • 10-Yr Bond

    0.9280
    -0.0200 (-2.11%)
     
  • Vix

    20.97
    -0.20 (-0.94%)
     
  • GBP/USD

    1.3470
    +0.0095 (+0.7072%)
     
  • USD/JPY

    103.7930
    -0.6310 (-0.6043%)
     
  • BTC-USD

    19,355.71
    +406.46 (+2.14%)
     
  • CMC Crypto 200

    380.45
    +6.04 (+1.61%)
     
  • FTSE 100

    6,462.55
    -0.84 (-0.01%)
     
  • Nikkei 225

    26,809.37
    +8.39 (+0.03%)
     

Reflecting on Epizyme's (NASDAQ:EPZM) Share Price Returns Over The Last Three Years

Simply Wall St
·3 min read

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But in any portfolio, there are likely to be some stocks that fall short of that benchmark. Unfortunately, that's been the case for longer term Epizyme, Inc. (NASDAQ:EPZM) shareholders, since the share price is down 38% in the last three years, falling well short of the market return of around 39%. Furthermore, it's down 27% in about a quarter. That's not much fun for holders.

View our latest analysis for Epizyme

Epizyme wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Over three years, Epizyme grew revenue at 21% per year. That's well above most other pre-profit companies. The share price drop of 11% per year over three years would be considered disappointing by many, so you might argue the company is getting little credit for its impressive revenue growth. It seems likely that actual growth fell short of shareholders' expectations. Still, with high hopes now tempered, now might prove to be an opportunity to buy.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So it makes a lot of sense to check out what analysts think Epizyme will earn in the future (free profit forecasts).

A Different Perspective

Epizyme provided a TSR of 5.9% over the last twelve months. But that return falls short of the market. But at least that's still a gain! Over five years the TSR has been a reduction of 3% per year, over five years. So this might be a sign the business has turned its fortunes around. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider risks, for instance. Every company has them, and we've spotted 3 warning signs for Epizyme you should know about.

Epizyme is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.